Author

R. D. Morin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

K. Dreval· 2 shared M. Alcaide· 2 shared N. Thomas· 2 shared S. E. Arthur· 2 shared A. Mottok· 1 shared A. Telenius· 1 shared B. Grande· 1 shared C. K. Rushton· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

K. Dreval

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivOct 14, 2021

Shared and distinct genetic features in human and canine B-cell lymphomas

K. M. Coyle, T. Hillman, M. Cheung…·R. D. Morin

This study compares genetic mutations in canine and human B-cell lymphomas, identifying shared and distinct features that may affect their biology and therapeutic development.

DOI 10.1182/bloodadvances.2021006429

humanmouse

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 22, 2021

Non-coding NFKBIZ 3' UTR mutations promote cell growth and resistance to targeted therapies in diffuse large B-cell lymphoma

S. E. Arthur, J. Gao, S. Healy…·R. D. Morin

This study identifies non-coding NFKBIZ 3' UTR mutations as drivers of DLBCL growth and resistance to NF-κB-targeted therapies, suggesting their potential as biomarkers.

DOI 10.1101/2021.05.22.445261

humanbulk RNA-seq

𝕏 PostBluesky